What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A c-Kit targeting fully human monoclonal antibody-drug conjugate with MMAE administered intravenously.”In the company’s words, NCT06805825 on ClinicalTrials.gov
- Tested for
- Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
- Main trialPhase 1
- “This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.”In the company’s words, NCT06805825 on ClinicalTrials.gov
Other drugs for Gastrointestinal Stromal Tumors
- RipretinibDeciphera Pharmaceuticals, LLC · Phase 3
- VelzatinibGSK · Phase 3
- NB003Ningbo Newbay Technology Development Co., Ltd · Phase 2/3
- BezuclastinibCogent Biosciences, Inc. · Phase 3
- InlexisertibDeciphera Pharmaceuticals, LLC · Phase 1/2
- KQB198Kumquat Biosciences Inc. · Phase 2
Coming up1
- 30 Aug 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 30 Aug 2027 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026